LigaChem Biosciences said on the 24th that it signed a technology licensing agreement with U.S. biotech company NovaRock Biotherapeutics for an antibody targeting a new anticancer target to develop an Antibody-Drug Conjugate (ADC) candidate.
This is an additional agreement separate from the two antibody licensing deals brought in from NovaRock in Jun. 2025.
Through this agreement, LigaChem Biosciences secured exclusive global rights for the development and commercialization of the ADC using the antibody. Specific terms, including target information and the deal size, were not disclosed.
The in-licensed antibody targets a new marker expressed in solid tumors with high unmet medical needs. LigaChem Biosciences plans to apply its ADC platform "ConjuALL" to identify next-generation ADC candidates.
Chief Executive Kim Yong-ju of LigaChem Biosciences said, "We have expanded our ADC pipeline through the collaboration with NovaRock," and added, "We will continue to discover and develop candidates."
Meanwhile, through its mid- to long-term strategy "VISION 2030," LigaChem Biosciences aims to secure 3–5 new ADC candidates each year and advance them into clinical stages. It is working to expand its pipeline through collaborations with partners at home and abroad, including NovaRock.